Can coronary thrombolysis meet the challenge of primary angioplasty?

Fibrinolysis

Volumn 10, Issue 3, 1996, Pages 137-142

  De Bono, D ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOCARDIOGRAPHY; BLOOD CLOT LYSIS; CORONARY ARTERY DISEASE; HUMAN; PRIORITY JOURNAL; RECANALIZATION; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 0029683753     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80024-5     Document Type: Review

References (35)

1. DeWood MA, Spores J, Notske R et al. Prevalence of total coronary occlusion during the early hours of myocardial infarction. New Engl J Med 1980; 303: 897-902.
2. Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden ischaemic cardiac death. New Engl J Med 1984; 310: 1137-40.
3. Falk E. Plaque rupture with severe pre-existing thrombosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50: 27-134.
4. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischaemic cell death: 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977; 56: 786-93.
5. Jennings RB, Reimer KA. Factors involved in salvaging ischaemic myocardium: effect of reperfusion of arterial blood. Circulation 1983; 68 (suppl. 1): 125-36.
6. Simoons ML, Arnold AER, Betriu A et al. Thrombolysis with tissue plasminogen activator in acute myocadial infarction: no additional benefit from immediate percutaneous angioplasty. Lancet 1988; i: 197-203.
7. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. New Engl J Med 1989; 320: 618-27.
8. Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, Fritz JK. The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12 month follow-up report. New Engl J Med 1985; 312: 1073-78.
9. Lamas GA, Flaher GC, Mitchell G et al. Effects of infarct artery patency on prognosis after acute myocardial infarction. Circulation 1995; 92: 1101-09.
10. Koren G, Weiss AT, Hasin Y et al. Prevention of myocardial damage in acute myocardial infarction by early treatment with intravenous streptokinase. New Engl J Med 1985; 313: 1384-89.
11. Rawles J, on behalf of the GREAT group. Halving of mortality at one year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1994; 23: 1-5.
12. The GUSTO angiographic investigators. The effects of tissue plasminogen activator, streptokinase or both on coronary artry patency, ventricular function and survival after acute myocardial infarction. New Engl J Med 1993; 329: 1615-22.
13. O'Neill W, Timmis GC, Bourdillon PD et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial intarction. New Engl J Med 1986; 314: 812-18.
14. Zijlstra F, de Boer M, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. New Engl J Med 1993; 328: 680-84.
15. Grines CL, Browne KF, Marco J et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. New Engl J Med 1993; 328: 673-79.
16. Anderson JL, Karagounis L, Lewis CB, Sorensen SG, Menlove RL for the TEAM-3 investigators. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Circulation 1993; 87: 1829-39.
17. Simes RJ, Topol EJ, Holmes DR et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete reperfusion. Circulation 1995; 91: 1923-28.
18. The EPIC investigators. Prevention of ischaemic complications in high risk angioplasty by a chimeric monoclonal antibody c7e3 Fab fragment directed against the platelet glycoprotein IIb/IIIa receptor. New Engl J Med 1994; 330: 956-61.
19. O'Keefe JH, Rutherford BD, McConohay DR et al. Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1989; 64: 1221-30.
20. Brush JE, Thompson S, Ciuffo AA et al. Retrospective comparison of a strategy of primary coronary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction in a community hospital without cardiac surgical backup. J Invas Cardiol 1996; 8: 91-8.
21. Colombo A, Hall P, Nakamura ? et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91: 1676-88.
22. Vanderscheuren S, Barrios L, Kerdsinchai P et al. A randomised trial of recombinant staphylokinase versus alteplase for coronary artery patency in myocardial infarction. Circulation 1995; 92: 2044-49.
23. Collen D. Fibrin selective thrombolytic therapy for myocardial infarction. Circulation 1996; 93: 857-65.
24. Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct related artery in acute myocardial infarction. Circulation 1995; 91: 2132-39.
25. Simoons ML, Arnold AER. Tailored thrombolytic therapy: a perspective. Circulation 1993; 88: 2556-64.
26. Vaughan DE, Van Hotte E, Declerck PJ, Collen D. Streptokinase induced platelet aggregation: prevalence and mechanism. Circulation 1991; 84: 84-91.
27. Niewarowski S, Senyi AF, Gillies P. Plasmin induced platelet aggregation and platelet release reaction. J Clin Invest 1973; 52: 1647-59.
28. Eisenberg P, Sobel B, Jaffe A. Activation of prothrombin accompanying thrombolysis with recombinant tissue type plasminogen activator. J Am Coll Cardiol 1992; 19: 1065-69.
29. Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacological concentrations of plasminogen activators in non-anticoagulated whole blood. Thromb Res 1989; 55: 635-43.
30. Gulba DC et al. Increased thrombin levels during fibrinolytic therapy in myocardial infarction. Circulation 1991 ; 83: 937-44.
31. Gibbons RJ, Holmes DR, Reeder GS et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. New Engl J Med 1993; 328: 685-91.
32. O'Neill WW, de Boer MJ, Gibbons RJ et al. Pooled analysis of three prospective randomized clinical trials of thrombolytic versus angioplasty therapy of acute myocardial infarction. J Am Coll Cardiol in press.
33. Riessen R, Isner JM. Prospects for site-specific delivery of pharmacologic and molecular therapies. J Am Coll Cardiol 1994; 23: 1234-44.
34. Meyer BJ. Fernandez-Ortiz A. Mailhac A et al. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation 1994; 90: 2474-80.
35. More RS, Underwood MJ, Brack MJ, Pringle S, de Bono DP, Gershlick AH. A targeted antithrombotic conjugate with antiplatelet and fibrinolytic properties which reduces in vivo thrombus formation. Cardiovascular Research. 1993; 27: 2200-04.